Werbung
Werbung
CVKD
Cadrenal Therapeutics, Inc. Common Stock
8.31
USDGesponsert
+0.43
+5.46%
09. Jan., 15:59 UTC -5
Geschlossen
Nach-Markt
8.37
+0.05
+0.66%
CVKD Ergebnisberichte
Positives Überraschungsverhältnis
CVKD übertreffen die 2 der letzten 8Schätzungen.
25%
Nächster Bericht
Datum des nächsten Berichts
11. März 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$1.20
Implizierte Änderung von Q3 25 (Revenue/ EPS)
--
/-8.40%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
--
/-56.20%
Cadrenal Therapeutics, Inc. Common Stock earnings per share and revenue
On 10. Nov. 2025, CVKD reported earnings of -1.31 USD per share (EPS) for Q3 25, beating the estimate of -1.55 USD, resulting in a 15.87% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -3.17% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -1.20 USD, with revenue projected to reach -- USD, implying an decrease of -8.40% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
What were Cadrenal Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Cadrenal Therapeutics, Inc. Common Stock reported EPS of -$1.31, beating estimates by 15.87%, and revenue of $0.00, 0% as expectations.
How did the market react to Cadrenal Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -3.17%, changed from $12.14 before the earnings release to $11.76 the day after.
When is Cadrenal Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 11. März 2026.
What are the forecasts for Cadrenal Therapeutics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Cadrenal Therapeutics, Inc. Common Stock is expected to report EPS of -$1.20 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung